SR One is the independent corporate venture capital arm of GlaxoSmithKline. They invest globally in emerging life science companies that are pursuing innovative science with significant impact on medical care. SR One has invested over $830MM in the health care industry.
We've partnered up with the Oxbridge Biotech Roundtable because of our shared missions of catalysing entrepreneurship. Together with OBR, we firmly believe that we can have a positive impact on human health by supporting visionary founders. We see OneStart as a vehicle to that end.
Read more at srone.com
I joined SR One in 2005 to establish the firm's European investment office. I have extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during more than 20 year tenure in the pharmaceutical industry. I am currently a member of the Board of Directors of Mission Therapeutics, Bicycle Therapeutics, Atopix Therapeutics, AtoxBio, f-star and VH Squared.
I came to SR One from TVM Capital where I was a Venture Partner, Entrepreneur-in-Residence and appointed CEO and President of SelectX Pharmaceuticals. Prior to that, I was a General Partner in TVMs Boston life sciences practice where I focused on earlier-stage investments. I am currently Chairman of the Board of Directors of Thrasos Therapeutics and a Director at Alios BioSciences. I was also the founder of Akikoa Pharmaceuticals, a biotechnology start-up company focusing on hearing loss, and North Haven Systems, a life science IT company.
I joined SR One in 2011 to take the lead in investing SR One's UK biotech fund. Prior to joining SR One I worked as a consultant for Longbow Capital Partners in London, and before that I was a Vice President of Greenhill & Co, an M&A Investment Bank and Private Equity firm.
I joined SR One in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and subsequently joined the team focusing on European investments. I bring a range of experience to SR One, including senior management roles in sales and marketing, commercial strategy and business development at Glaxo Wellcome, Cephalon, Medical Venture Management, The Automation Partnership and Galapagos. I have significant deal making experience in the pharmaceutical and biotech sectors and has run a number of successful businesses deriving healthy exits for investors.
I joined SR One in 2011 with a background in biotech partnering and commercial development. Prior to SR One, I was responsible for Corporate Development at Dynavax Technologies, where I was involved in multiple pharma partnering deals as well as substantial private and public financings. Previously, I was a consultant specializing in health care at Clearview Projects and Mercer Management Consulting.
I joined SR One in January 2011, after interning with SR One since 2009. Prior to joining SR One, I was a consultant at McKinsey & Co, a co-founder of Extera Partners, and a business development manager at Infinity Pharmaceuticals. Over my career, I have supported business and corporate development activities for nearly 50 large and small public, venture-backed, and angel funded life science companies.
Semi-finalist WaveCap - Oxford, United Kingdom - Non-invasive neurostimulation for early onset seizure detection & treatment using novel machine learning algorithm on EEG